Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 306

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 306
---
 experience delays in developing and deploying remedial measures
designed to address any such identified vulnerabilities.

Any of the previously identified or similar threats
could cause a cybersecurity incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification,
destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those
of the third parties upon whom we rely. A cybersecurity incident or other interruption could disrupt our ability (and that of third parties
upon whom we rely) to provide our services, develop our products, and conduct clinical trials.

The costs related to significant cybersecurity
incidents or disruptions could be material and cause us to incur significant expenses. If the information technology systems of our clinical
sites, and other contractors and consultants become subject to disruptions or cybersecurity incidents, we may have insufficient recourse
against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and
implement protections to prevent future events of this nature from occurring.

We may expend significant resources or modify our
business activities (including our clinical trial activities) in an effort to protect against cybersecurity incidents. Certain data privacy
and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security
measures to protect our information technology systems and data. Despite the implementation of security measures in an effort to protect
systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal
information technology systems, and those of third parties upon which we rely (including sites performing our clinical trials), there
can be no assurance that these measures will be effective. We also cannot be sure that our insurance coverage will be adequate or sufficient
to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be
available on commercially reasonable terms or at all, or that such coverage will pay future claims.

65

If any cybersecurity incidents referenced above
were to occur and cause interruptions in our operations, it could result in a disruption of our business and development programs. For
example, the loss of clinical trial data from completed or ongoing clinical trials for a drug candidate could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data or may limit our ability to effectively
execute a product recall, if required in the future. To the extent that any disruption or cybersecurity incident were to result in the
loss of or damage